PharmaGend Project
- 29 December, 2023
- By Rxilient
On 29 December, 2023, Rxilient Health Pte. Ltd. (“Rxilient Health”) is pleased to announce that PharmaGend Global Medical Services Pte. Ltd. (“PharmaGend”), jointly invested by Rxilient Health, and its main shareholder CMS, through its wholly-owner affiliate CMS MEDICAL VENTURE PTE. LTD., with Pharmaron (Hong Kong) International Limited (“Pharmaron”) * and HEALTHY GOAL LIMITED (“Legend Fund”), has entered into a lease agreement for the building and property located in Tuas, Singapore and completed the purchase of certain production machines and equipment from Strides Pharma Global Pte. Ltd. ( defined as “Singapore manufacturing plant ”).
The Singapore manufacturing plant has advanced manufacturing machines, equipment and first-class infrastructure. It had been approved by Health Sciences Authority of Singapore (HSA), U.S. Food and Drug Administration (FDA) and Therapeutic Goods Administration of Australia (TGA). It will serve as the plant and site for PharmaGend to carry out pharmaceutical formulation, finishing, and packaging business, accelerating the formulation Contract Development and Manufacturing Organization (formulation CDMO) business development in Singapore. These progresses will promote the globalization, high-quality, and sustainable healthy development of cooperative parties, and are expected to improve the accessibility of high-quality drugs with unmet clinical needs in emerging markets.
Singapore Manufacturing Plant
*PharmaGend is 33.8% owned by CMS’s wholly-owned subsidiary, and 11.2% owned by Rxilient Health, 35% owned by Pharmaron, and 20% owned by Legend Fund.
